Disclaimer: Analysis and opinion, not medical advice. I am not a doctor or scientist, I am a finance guy who looks at industries for a living and a guy who loves bikes, skis and mountain sports. Do your own research, talk to actual physicians, and don’t take any of this as a recommendation to put anything in your body.
In April 2026, FDA removed several peptide-related bulk drug substances from Category 2 after nominations were withdrawn, while also scheduling a July 2026 Pharmacy Compounding Advisory Committee review for several of those substances. Six weeks earlier US Health and Human Services Chief RFK Jr. made very positive comments regarding peptides on the Joe Rogan Podcast. Rumors have been swirling since mid 2025 that the administration was going to be easing restrictions on this less-than-mainstream category of substances and by many accounts, a path is cleared for peptides to go center-stage in fitness communities.
This change made me wonder whether peptides are about to move from the gray-market, bro-science, research-chem, reddit world into something much more mainstream: telehealth, compounding pharmacies, longevity clinics, performance medicine, and maybe eventually targeted directly at the outdoor athlete.
The bigger question is whether a new medicalized performance category gets built around the outdoor industry’s best (affluent, older) customers, with better recurring revenue, better margins, and higher LTV than most outdoor brands will ever see.
That may seem like an odd question for an outdoor-industry Substack until you look at what has happened with GLP-1s, TRT, CGMs, medspas, and the broader optimization economy. Medical tools, vanity drugs, hormone protocols, and clinical devices are moving into consumer culture faster than most industries know how to process, and billions of dollars are being minted on behalf of these compounds.
With all of that said, I wanted to distill this down to one simple two part question: Are peptides coming for outdoor sports and if they are, who captures the value?
To answer this, we’re going to breakdown what peptides are, and the four “gates” they must pass in order to have a shot at going mainstream:
- Regulation: Trump Administration steamrolls a path for them to be prescribed legally and above board.
- Efficacy: They work. Like…they really work.
- Safety: They are safe. No massive side effect profile.
- Culture: We look at peptides the same way we look at GLP-1s, not the way we look at anabolic steroids.
Finally, I’m going to speculate what kind of businesses we might see built on-top of these compounds and what it might mean for those of us who are passionate (maybe aging) outdoor athletes.
Let’s dig in…
1:31:30 you can hear RFJ Jr’s take on peptides and what in part spurred this post. To be very clear, I do not seek medical advice from Rogan or RFK Jr. You do you, though.
What Are Peptides?
Peptides are short chains of amino acids. Your body makes them naturally, and some very real medicines are peptides or peptide-like drugs. Insulin is a peptide hormone. GLP-1 is a peptide hormone. Semaglutide, better known by brand names like Ozempic and Wegovy, works by targeting the GLP-1 pathway.
Peptide is a category, not a product. Saying someone is “on peptides” does not tell you much until you know which compound, what dose, what source, what route, and what supervision.
This brings us to the first crux; the word “peptide” is a marketing opportunity. “Peptide” not only is not associated with anything in most people’s had, it also does not sound like “steroid” or “research chemical”. It sounds biological, targeted, modern, and maybe just natural enough for the wellness world to run with it.
For this conversation, the relevant compounds (part of the reg change) mostly fall into three buckets.
The first is repair and recovery: BPC-157, TB-500, GHK-Cu, KPV, and similar compounds. These are marketed around tendon healing, ligament repair, inflammation, collagen, skin, gut issues, and general tissue recovery. This is the bucket that maps most obviously to the outdoor athlete, because almost every aging skier, cyclist, runner, moto rider, climber, and mountain athlete has something that has not healed the way they hoped it would.
The second is the growth hormone axis: CJC-1295, ipamorelin, sermorelin, tesamorelin, and similar compounds. These are usually marketed around sleep, recovery, lean mass, body composition, and feeling less destroyed by the same training load. This is where the masters racer, the overtrained founder, and the aging endurance athlete start to pay attention.
The third is the metabolic, mitochondrial, and longevity bucket: MOTs-C, AOD-9604, Epitalon, Semax, and others. This is the fuzzier zone, but it plugs neatly into the broader longevity movement: better mitochondria, better aging, better cognition, better metabolic health, maybe better endurance.
The science varies wildly by compound. Peptides are not snake oil as a category. GLP-1s are peptides, and they are among the most commercially successful drugs of the decade. However, most of the peptides being discussed in the performance, recovery, and longevity world are nowhere near that level of evidence, which we will get into in the next section.
Gate 1: Efficacy
The first gate is the obvious one: do these compounds actually work?
Peptides absolutely work as a category. Insulin is a peptide. Again, GLP-1 is a peptide. However, this does not mean every peptide being marketed to aging athletes, gym guys, biohackers, and longevity enthusiasts works the way the marketing or bro-science influencer implies.
This is where the category gets messy. Some of these compounds have legitimate medical use cases. Tesamorelin, for example, has randomized clinical trial data showing reductions in visceral fat in HIV-associated lipodystrophy, which is a very specific medical indication and not the same as “your 48-year-old riding buddy will recover faster from intervals.” CJC-1295 has human data showing sustained increases in growth hormone and IGF-1 in healthy adults, which tells us it does something biologically real, but does not prove it improves recovery, sleep, body composition, or performance in healthy athletes, which is how it is currently marketed in the gray market.
Next up is the recovery bucket, which is probably the most interesting for outdoor sports and the least proven relative to the hype.
BPC-157 is the flagship example. The animal data is interesting, and the story is almost perfectly designed for banged up athletes: tendon healing, ligament repair, inflammation, gut issues, chronic pain, and the nagging injury that never quite goes away. But the human evidence is (incredibly) thin. Recent sports-medicine commentary has noted that there is no high-quality clinical evidence in human subjects supporting BPC-157, and no large multicenter trials evaluating safety, dosage, or long-term use in athletes. This does not mean BPC-157 is fake but I would suggest the certainty is fake and the reality is to be determined.
The same general pattern applies across much of the category. There is mechanistic plausibility, animal studies, biomarkers, anecdotes, podcasts, Reddit threads, clinics, people saying, with complete confidence, that some peptide fixed the elbow, knee, Achilles, shoulder, gut, sleep, or recovery problem that nothing else fixed. Some of these people probably are right, some placebo, but none of it is to be confused with the scientific method. Put simply, the current evidence base is nowhere near the confidence level of the marketing.
This is why I feel strongly the first gate is efficacy. If these compounds do nothing meaningful in healthy humans, this becomes the snake-oil gold rush of 2026 (or likely 2027). There will still be money made, because humans are humans, placebo is unarguable and hope is a business model, but it will eventually burn out.
If, on the other hand, even a few of these compounds genuinely help a meaningful subset of aging athletes recover faster, heal better, sleep deeper, preserve lean mass, or tolerate training load more effectively, the category gets very interesting very quickly. To add, they do not need to work like GLP-1s to matter, they just need to work well enough that they move the needle for a good chunk of the population who tries them, where word of mouth type advertising alone begins to do the heavy lifting.
In endurance and mountain-sport communities, this is often how products move, not through pure-bread science but through trusted anecdote, repeated often enough, from people who still look like they are doing the thing.
Somewhere in there is the line between niche bro science, science, and the real market.
Jeff’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
Gate 2: Regulation
The second gate is regulatory, and this is the change that prompted the piece.
The backdrop is shifting, but not in the simplistic “peptides are now approved” way some people will inevitably claim. FDA has scheduled a July 2026 Pharmacy Compounding Advisory Committee review of several peptide-related bulk drug substances, including BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, and Epitalon, for possible inclusion on the 503A Bulks List. Please understand this is a compounding decision, not normal FDA drug approval. None of these are being approved as commercial drug products for healthy athletes trying to recover faster by the FDA.
Inclusion on the 503A Bulks List would mean certain licensed compounding pharmacies may be able to use those bulk substances under specific conditions. It would not mean FDA has determined these compounds are safe and effective in the way it has for approved drugs. FDA’s April 2026 update also notes that several substances were removed from Category 2 because nominations were withdrawn, but removal alone does not equal approval or automatic eligibility.
Commercially, though, the shift matters a lot. Demand did not disappear when compounding access narrowed in 2023 but it moved into gray-market channels: research-use-only vials, overseas suppliers, Reddit protocols, and websites that sit somewhere between supplement commerce and experimental pharmacology. If the review process moves in a permissive direction, even partially, the customer base expands from people willing to buy sketchy vials online with APIs that are highly questionable to people willing to fill out a telehealth intake form, talk to a physician, and pay monthly for a protocol that feels medically supervised.
This unlock legitimizes the space, not because the science is settled, but because the channel changes (and vials hypothetically less sketchy).
A final point, a peptide becoming legally compoundable would not make it legal in sport. FDA/503A status and anti-doping status are completely different regimes. For practical purposes, athletes governed by WADA rules should assume the main peptides in this conversation are prohibited unless specifically cleared through proper anti-doping channels. Some fall under WADA’s broad categories for peptide hormones, growth factors, related substances, and mimetics. Others, like BPC-157, are prohibited under WADA’s S0 category for unapproved substances. Legal to prescribe and legal to race on are not the same thing.
Gate 3: Safety
The third gate is safety, and this is where the category gets harder to wave away but also harder to responsibly endorse.
I’m going to type this again. None of the core peptide substances currently being reconsidered for 503A compounding, including BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon, and DSIP, should be confused with FDA-approved drugs.
The review is about whether they may be used as bulk substances in compounding, not whether FDA has approved them as safe and effective commercial drug products. The safety profile here is unresolved and hardly reassuring.
The concern is not that every compound in this category is obviously dangerous but rather the concern is that many of them have (incredibly) limited human safety data, especially for the way the wellness market wants to use them: healthy people, chronic use, multiple compounds stacked together, often combined with TRT, GLP-1s, supplements, hard training, under-sleeping, and (currently/sometimes) less-than-perfect sourcing
FDA’s safety concerns around several of these bulk substances include limited or absent human exposure data, possible immunogenicity, peptide-related impurities, aggregation, and difficulty characterizing the active pharmaceutical ingredient. For some compounds, FDA’s position is essentially: we do not have enough information to know whether this would cause harm if administered to humans through the proposed route. That is not the same as saying harm is proven, but it is also a very long way from saying the category is safe.
Lets talk sourcing for a second; a peptide from a licensed compounding pharmacy is not the same thing as a research-use-only vial bought online with sketchy origin, but compounding is not magic either. The nightmare case in the back of everyone’s mind is the 2012 New England Compounding Center fungal meningitis outbreak, which was tied to contaminated compounded steroid injections and led to 64 deaths and hundreds of illnesses. Don’t misread, this does not mean compounding pharmacies are broadly unsafe, but it should kill the idea that “compounded legally” automatically means risk-free. There is always risk here.
This is one reason why safety may be a headwind, but not necessarily a blocker.
Americans are strange about risk. Lack of safety data is treated very differently than clear evidence of harm. A meaningful percentage of consumers already distrust FDA, trust their doctor selectively, trust their favorite podcast guest more than they probably should, and are willing to experiment if the promised upside touches pain, aging, body composition, sleep, or identity. Sex & vanity sells, and in a way, that is what is being sold here.
So long as there is a physician-adjacent channel, a plausible mechanism, a friend with a success story, and a bro-science influencer willing to say the quiet part loudly, I do not think limited safety data alone stops the category. Joe Rogan’s endorsement alone matters more than the FDA to much of the population. (and I’m not kidding)
That said, if a serious side effect becomes culturally legible, especially around cancer, cardiac risk, contamination, or a high-profile injury/death, the whole category changes overnight. The market can live with uncertainty but it may not survive a simple, terrifying story that everyone understands. Narratives, stories and how they spread through a community is fascinating and this one is yet to be written.
That is the safety gate: not perfect proof of safety, but enough perceived safety for consumers, clinics, telehealth platforms, and insurers’ lawyers to tolerate the risk and at minimum “take the leap”.
Gate 4: Culture
The final gate is culture, and this may be the most important one.
The million-dollar billion-dollar, question is how the outdoor world will perceive peptides. Historically, any compound that was truly performance-enhancing and banned by WADA carried enormous reputational risk if you were serious about your sport. If you were caught, even in the masters/vet ranks, you were not just penalized, you were effectively exiled from your community.
That still applies at the elite level. If you are a professional racer, an Olympic hopeful, or anyone operating inside a real anti-doping regime, the answer is simple: if you use a banned peptide without a valid exemption, you are doping. There is no clever wellness framing that gets around that.
However, the outdoor world is not made entirely of elite athletes, and many of those once-super-serious athletes are getting much older.
Most of this probably lives in the messy middle: masters racers, age-groupers, amateur gravel athletes, local enduro guys, ski mountaineers, ultra runners, big-day enthusiasts, washed-up former racers, and people who do not race at all but still build a huge part of their identity around what their body can do.
If a 57-year-old who never sits in a start gate uses a peptide under medical supervision because his shoulder finally stops hurting and he can ski tour again, most people probably will not care. If a 47-year-old masters racer uses the same compound while chasing age-group podiums, people may care a lot. If a respected older athlete starts talking publicly about a “recovery protocol,” the conversation gets murkier still. Doping is a problem at all levels of endurance sports, and this most certainly will make it worse.
Competition aside, the word “peptide” is currently a blank canvas for most normal people. It does not yet carry the cultural baggage of “steroid.” It does not automatically sound like “EPO.” It sits somewhere between supplement, medicine, longevity hack, and PED, depending on who is saying it and how they are selling it. I’d argue that blankness is the opportunity and the risk.
If peptides become GLP-1-coded, meaning doctor-supervised, wellness-adjacent, medically legitimate, and increasingly normal, the category can grow quickly. If they become PED-coded, meaning cheating, needles, sketchy vials, and banned-substance headlines, the outdoor world will push them into the shadows (though they’ll still be used).
Marketing, PR, influencers and who adopts first will really influence the outcome here, especially in our space. This is where we have to talk about the phenomena of “bro science”.
Peptides are not entering the conversation because most people read clinical literature, they are entering the conversation because of Rogan, Huberman, Attia, RFK Jr. and guys like Bryan Johnson. Forums, gyms, Reddit threads, podcasts, longevity doctors, supplement-adjacent influencers, and high-agency middle-aged men with sore tendons started experimenting before the institutions caught up. Without this trend, I don’t think we’re talking about anything at all.
It is the messy, anecdotal, socially transmitted layer that takes a compound from obscure molecule to “hmmm, yeah, maybe I could take that”. While I’m no expert, it sure seems like this is how a lot of performance culture actually moves. “Peer review is for the nerds, I only care about how it’ll help me.” Story, repetition, trusted anecdotes, and the guy who still looks fast telling you what finally fixed his knee is what counts.
This gate is super tricky. It has to become socially acceptable enough that the customer does not feel like a cheater, a lab rat, or a fool. If that happens, the category gets very interesting in our space, specifically.
If it does not, peptides may still grow, but they will grow quietly, awkwardly, and with the same half-hidden energy that already surrounds a lot of amateur performance enhancement.
What Kind of Businesses Get Built?
Before getting into the businesses, it is worth remembering the size of the adjacent markets.
GLP-1 weight-loss drugs were already a roughly $13.8 billion global market in 2024 and are projected to reach nearly $49 billion by 2030. The broader GLP-1 market could be much larger. Morgan Stanley recently estimated the global GLP-1 market could reach $190 billion by 2035.
TRT is much smaller, but culturally important. It helped normalize the idea that aging men should manage, optimize, and subscribe their way around decline. Sports supplements are the old-world comp: big, competitive, and relatively low switching cost. Depending on definition, sports supplement estimates range widely, but the broader category is clearly large and crowded.
Peptides sit somewhere between all of these: the medicalized-consumer-health logic of GLP-1s, the aging-male-optimization logic of TRT, the marginal-gains psychology of supplements, and the cash-pay model of medspas and longevity clinics. Plus, they have a much larger range of “coverage”.
The outdoor industry looks at an aging athlete with more money than sense and sees a gear customer, event customer, maybe a coaching customer. A performance medicine company looks at the same person and sees someone who might pay $200 to $500+ per month for labs, prescriptions, protocols, follow-up, and the promise of more years doing the thing. At the high end, these users will happily pay $12-24K per year for the shot at “feeling 10 years younger again”./
That is a very different customer-value equation than literally anything else in the outdoor industry. Also, for those that pay attention to my writing, we’re firmly talking about customers on the right side of the barbell.
Telehealth
Telehealth is the most obvious category and probably the first to scale.
The model already exists: intake form, physician consult, prescription if appropriate, recurring billing, pharmacy fulfillment, and retention marketing. Hims, Ro, LifeMD, Hone, Henry, Maximus, Marek, and others have trained consumers to buy private, awkward, vanity-adjacent, or optimization-adjacent health products online.
Hims is the cleanest public comp. In 2025, Hims & Hers did roughly $2.35 billion of revenue, up 59%, with $128 million of net income, $318 million of adjusted EBITDA, and more than 2.5 million subscribers.
Lets talk marketing, because its the most important part. Hims is really more of a customer-acquisition machine with a healthcare wrapper than a medical practice. The company spent $919.3 million on marketing in 2025, including $798.5 million of customer acquisition costs. Yikes. That is an absurd amount of money on marketing.
The peptide winner may not be the company with the best molecule (they should be commoditized) but rather may be the company that tells the cleanest story, buys the customer efficiently, makes the intake process feel safe, is specific about what they sell and keeps the patient subscribed long enough for the math to work. Remember, just like TRT or GLP-1s, switching cost (to another provider) is really just the willingness of the consumer to go fill out paperwork elsewhere. This will be one of the challenges as competitors flood the zone.
If the outdoor-athlete version of this category gets built, it will not start with a white paper or something nerdy. It will start with ad copy, podcast reads, athlete testimonials, landing pages, before-and-after stories, and carefully chosen words that make “WADA-banned injectable compound with limited human data” sound more like “doctor-supervised recovery optimization.”
Performance Clinics
The second business is the in-person version.
Call it a longevity clinic, performance medicine practice, recovery clinic, or, because I cannot help myself, the ManSpa.
The offer is not just peptides but a full service in person experience to get you to your best self. This includes labs, hormones, recovery protocols, DEXA scans, VO2 testing, red light therapy, hyperbaric oxygen, IVs, PT, massage, cryotherapy, sleep work, and coaching relationships. This already exists. It just hasn’t quiet been marketed right to this demographic and nobody has cracked the code on a franchise basis.
The medspa market is the closest analog. Grand View Research estimates the global medical spa market was about $21.2 billion in 2024 and projects it to reach $78.2 billion by 2033. (read those numbers again…woah)
A performance clinic for aging outdoor athletes could do something similar in places like Bend, Boulder, Bozeman, Park City, Jackson, Truckee, Asheville, Bentonville, and Salt Lake. These towns are full of aging athletes with money, injuries, identity, and a strong desire not to become the person they fear they are becoming.
The clinic model has better trust than pure telehealth, but worse operating complexity. You need leases, staff, medical directors, compliance, insurance, and local execution against a much smaller customer base. That makes it harder to scale and hypothetically run, but potentially more defensible if the brand becomes trusted and with real relationships – meaning switching costs are hypothetically higher.
Compounding Pharmacies
The third winner is less sexy but obvious: compounding pharmacies.
If a more legitimate pathway opens, licensed compounding pharmacies become the supply chain behind the category. Telehealth companies need them. Clinics need them. Physicians need them. Patients may never know who filled the prescription, but the infrastructure is obviously important, and needs to be there.
The opportunity is more prescriptions, more volume, and more recurring supply. The risk is that compounding also sits close to the blast radius if there is a contamination event, dosing issue, purity problem, or adverse-event cluster.
Testing and Trust
The fourth business is the trust layer.
If peptides move from gray market to semi-mainstream, people will need help answering basic questions. Is this product real? Is it pure? Is this clinic legitimate? Is this protocol legal? Is it WADA-prohibited? Is this claim nonsense?
That creates room for third-party testing, certification, compliance, patient education, coach education, anti-doping guidance, batch verification, and maybe even a “clean sport” counter-position for athletes and brands that want nothing to do with any of this.
Bringing It Together
Here is my breakdown of the basic operating model:
- Bro science creates the demand.
- Telehealth professionalizes the funnel.
- Compounding pharmacies provide the supply chain.
- Clinics create trust.
- Marketing turns it into a category.
Conclusion
As Warren Buffett said, markets are voting machines in the short term and weighing machines in the long run. That feels like the right frame here. In the short term, I think peptides are going to get plenty of votes, heck in many ways they already are.
A gold rush does not require perfect science, clean safety data, settled regulation, or a fully resolved ethical framework. It only requires enough demand, enough belief, enough legal daylight, and enough businesses willing to move before the answer is obvious.
Peptides appear to have that setup: regulatory reconsideration, gray-market demand, bro-science momentum, telehealth distribution, compounding pharmacy infrastructure, aging athletes with money, and a culture increasingly comfortable medicalizing weight loss, hormones, sleep, recovery, and performance.
That is probably enough for money to be made in the short term.
The longer-term question is whether the four gates hold. The regulatory path has to stay open enough for legitimate companies to operate. The compounds have to work well enough for customers to keep paying. The safety profile has to avoid a simple, terrifying story that stops the market cold. Culture has to decide peptides feel closer to GLP-1s, TRT, and recovery medicine than steroids, EPO, and cheating.
If those gates hold, peptides could become part of the aging-athlete optimization stack. If they do not, the category may get pushed back into the shadows as another overhyped bro-science boom.
My base case is simple: the gold rush happens first, and the reckoning comes later.
Businesses will get built before the answer is clear. Many of them will look less like outdoor companies and more like telehealth platforms, compounding pharmacies, longevity clinics, and mountain-town performance practices.
The outdoor industry, and the broader fitness industry, should understand what is likely coming: the rapid medicalization of performance, recovery, and aging.
In some ways, this is not that different from e-bikes, hiking exoskeletons, recovery boots, or any other technology that helps people go farther, stay out longer, and keep doing the things they love. The difference is that this time the technology may not be bolted to the bike, worn on the body, or plugged into the wall.
It may be biological.
As always, thank you to my audience for taking the time to read my writing. If you like it, share it with a friend and if you can, become a paid subscriber. The more people who read my work the more I can do this sort of thing. Cheers!
To contact – jeff.brines@gmail.com
Citations/Further Reading
Regulatory / FDA
FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
Best primary source for the upcoming PCAC review of BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, and Epitalon for potential inclusion on the 503A Bulks List. (U.S. Food and Drug Administration)
FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
Best primary source for the April 2026 update, Category 2 removals after withdrawn nominations, and future review timing for substances like GHK-Cu. (U.S. Food and Drug Administration)
Reuters: FDA to convene expert panel to review wider access to some peptides
Good mainstream business/news source explaining the FDA review, RFK Jr. context, limited evidence, and compounding angle. (Reuters)
RAPS: FDA considers adding a dozen peptides to its bulk drug compounding list
Good regulatory-industry source if you want a less legalistic summary than FDA’s own docs. (raps.org)
WADA / Anti-Doping
WADA: 2026 Prohibited List
Primary source for WADA’s prohibited categories, including S0 non-approved substances and S2 peptide hormones, growth factors, related substances, and mimetics. (Wada Ama)
WADA: 2026 Prohibited List now in force
Cleaner public-facing WADA explainer that the 2026 list is active and includes S1 anabolic agents, S2 peptide hormones/growth factors, and related categories. (Wada Ama)
USADA: BPC-157 Experimental Peptide Prohibited
Best source for the specific BPC-157 anti-doping point. USADA states BPC-157 is prohibited under WADA’s S0 Unapproved Substances category and is not approved for human clinical use by any global regulatory authority. (NPC Hello)
USADA: Key changes on the 2022 Prohibited List
Useful for noting that BPC-157 was added to the WADA Prohibited List under S0 in 2022. (NPC Hello)
AP: Doping at your doorstep
Good mainstream source on research peptides, online access, WADA concerns, and the anti-doping enforcement problem. (apnews.com)
Science / Efficacy
American Orthopaedic Society for Sports Medicine: The Boom of Peptides in Sports Medicine
Very useful for your efficacy section. It states there is no high-quality human clinical evidence supporting BPC-157 and no large multicenter trials evaluating safety, dosage, or long-term use in athletes. (AOSSM)
McMaster University: What do we know about “research only” peptides?
Excellent plain-English academic source. It notes that a 2025 review found only three published human studies on BPC-157, totaling fewer than 30 subjects, with no randomized placebo-controlled design. (McMaster News)
Narrative review of BPC-157
Useful deeper scientific source if you want to reference the mechanistic and preclinical literature without overclaiming human efficacy. (PMC)
CJC-1295 human GH/IGF-1 study
Best source for the “biologically active but not outcome-proven” point. CJC-1295 increased GH and IGF-1 in healthy adults, which proves biological activity but not athletic recovery or longevity outcomes. (PMC)
Thymosin beta-4 wound healing phase 2 data
Good for showing that some peptide-related compounds have real human wound-healing evidence, while still being careful not to overgeneralize that into athletic recovery claims. (PubMed)
Tesamorelin information from MedlinePlus
Good conservative medical source for tesamorelin as an approved drug for HIV-associated lipodystrophy, and specifically not a weight-loss drug. (MedlinePlus)
Safety / Risk
FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
Best source for safety language. FDA discusses limited human exposure data, immunogenicity, impurities, aggregation, characterization issues, and uncertainty around potential harm. (U.S. Food and Drug Administration)
Washington Post: FDA weighs lifting peptide restrictions
Good mainstream source on the wellness craze, RFK Jr. support, FDA concerns, and critics warning about unknown health risks. (The Washington Post)
AP: Unproven peptides spreading through influencers and RFK Jr. allies
Strong source for the bro-science, influencer, wellness-clinic, and limited-evidence angle. (apnews.com)
DOJ: New England Compounding Center fungal meningitis outbreak
Best source for the compounding-pharmacy risk example. DOJ notes 64 deaths and hundreds of infections tied to contaminated compounded steroid injections. (Hims Inc.)
Market Size / Business Comps
Hims & Hers 2025 financial results
Best public telehealth comp. Hims reported roughly $2.35B in 2025 revenue, $128M net income, $318M adjusted EBITDA, and more than 2.5M subscribers. (Hims Inc.)
Hims & Hers 2025 shareholder letter / filings
Useful if you want to cite marketing/customer acquisition spend. Hims spent heavily on marketing and customer acquisition in 2025, which supports your point that this is a customer-acquisition machine with a healthcare wrapper. (Q4 Diagnostics)
Grand View Research: GLP-1 weight-loss drugs market
Good source for the GLP-1 market size: $13.84B in 2024, projected to $48.84B by 2030. (Grand View Research)
Morgan Stanley: Obesity drugs are scaling fast
Good source for the bigger GLP-1/incretin market framing. Morgan Stanley estimates the type-2 diabetes and obesity treatment market could reach $190B by 2035. (Morgan Stanley)
MarketDataForecast: Testosterone Replacement Therapy market
Good source for TRT market size: $2.29B in 2024, $2.41B in 2025, projected to $3.62B by 2033. (Market Data Forecast)
Fortune Business Insights: Sports Supplements Market
Good source for the narrower sports supplement market: $9.53B in 2024, projected to $17.57B by 2032. (Fortune Business Insights)
Fortune Business Insights: Sports Nutrition Market
Good broader sports nutrition comp: $59.13B in 2025, projected to $114.52B by 2034. (Fortune Business Insights)
Grand View Research: Medical Spa Market
Best medspa comp: $21.21B in 2024, projected to $78.23B by 2033. (Grand View Research)
Consumer Optimization / Adjacent Trend
FDA: First over-the-counter continuous glucose monitor cleared
Good source for the “clinical tools becoming consumer optimization products” point. FDA cleared Dexcom Stelo for adults not using insulin, including people without diabetes who want to understand how diet and exercise affect blood sugar. (U.S. Food and Drug Administration)
Reuters: FDA clears first OTC continuous glucose monitor
Good mainstream source on the same CGM point. (Reuters)